| P50 | author | Ester Gea-Mallorquí | Q57015424 |
| P2093 | author name string | Joan Joseph | |
| | Josep Maria Gatell | |
| | Narcís Saubi | |
| | Tomáš Hanke | |
| | Maximillian Rosario | |
| | Alice Mbewe-Mvula | |
| P2860 | cites work | The stability and immunogenicity of a dispersed-grown freeze-dried pasteur BCG vaccine | Q52126049 |
| | A historical and molecular phylogeny of BCG strains. | Q53557023 |
| | Preparation of a working seed lot of BCG and quality control by PCR genotyping. | Q54428525 |
| | Construction of the gyrB Database for the Identification and Classification of Bacteria | Q56880460 |
| | Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors | Q57078025 |
| | Lymphoproliferative Responses to Recombinant HIV‐1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines | Q57953852 |
| | Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines | Q59098577 |
| | Influence of Mycobacterium bovis Bacillus Calmette-Guerin on Antibody and Cytokine Responses to Human Neonatal Vaccination | Q62737130 |
| | BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics | Q70605977 |
| | Identification of substrains of BCG vaccine using multiplex PCR | Q73563166 |
| | HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers | Q79923228 |
| | Revised BCG vaccination guidelines for infants at risk for HIV infection | Q80383323 |
| | Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women | Q81481608 |
| | Design and pre-clinical evaluation of a universal HIV-1 vaccine | Q21092234 |
| | Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence | Q22122411 |
| | A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa | Q22242666 |
| | Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage | Q24531468 |
| | Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Q24648628 |
| | New use of BCG for recombinant vaccines | Q29615313 |
| | Comparative genomics of BCG vaccines by whole-genome DNA microarray | Q29618558 |
| | Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. | Q30485791 |
| | An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. | Q33570776 |
| | Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice | Q33584559 |
| | Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals | Q33795512 |
| | Dual neonate vaccine platform against HIV-1 and M. tuberculosis | Q33908584 |
| | Differentiation of clinical Mycobacterium tuberculosis complex isolates by gyrB DNA sequence polymorphism analysis | Q33969549 |
| | Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guérin, and Mycobacterium tuberculosis H37Rv by allelic exchange. | Q33992655 |
| | Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity | Q34045678 |
| | Codon usage in the Mycobacterium tuberculosis complex | Q34063767 |
| | Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. | Q34353428 |
| | Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans | Q34361636 |
| | Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. | Q34491796 |
| | Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes | Q34983688 |
| | Evaluation of genotype MTBC assay for differentiation of clinical Mycobacterium tuberculosis complex isolates | Q35026827 |
| | Whole-genome sequences of four Mycobacterium bovis BCG vaccine strains | Q35096242 |
| | Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control | Q35909944 |
| | Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding | Q35947967 |
| | The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells. | Q36315838 |
| | Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine | Q36361980 |
| | Assessment of genetic markers for species differentiation within the Mycobacterium tuberculosis complex | Q36530532 |
| | PCR identification of Mycobacterium bovis BCG | Q36543379 |
| | Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges | Q36690291 |
| | Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses | Q37191912 |
| | Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis | Q37274874 |
| | Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. | Q37328670 |
| | Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi | Q37387851 |
| | The species Mycobacterium africanum in the light of new molecular markers | Q37511249 |
| | Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration | Q38660460 |
| | Specific differentiation between Mycobacterium bovis BCG and virulent strains of the Mycobacterium tuberculosis complex. | Q39555355 |
| | Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids | Q39723660 |
| | Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors | Q42165676 |
| | Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques | Q42738025 |
| | Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: protection against Bordetella pertussis challenge in neonates. | Q43271063 |
| | Effect of plasmid copy number and lac operator sequence on antibiotic-free plasmid selection by operator-repressor titration in Escherichia coli | Q45071360 |
| | Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination | Q45176035 |
| | A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons | Q45180808 |
| | Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen | Q45236822 |
| | Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies. | Q45363198 |
| | Recombinant bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia | Q45759129 |
| | Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya | Q46958770 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e42559 | |
| P577 | publication date | 2012-08-21 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG | |
| P478 | volume | 7 | |